Innoviva (INVA) Competitors $19.20 -0.20 (-1.03%) Closing price 07/3/2025 01:23 PM EasternExtended Trading$19.20 0.00 (0.00%) As of 07/3/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INVA vs. ALKS, LGND, BCRX, FOLD, CLDX, DVAX, MNKD, NVAX, OPK, and GERNShould you be buying Innoviva stock or one of its competitors? The main competitors of Innoviva include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry. Innoviva vs. Its Competitors Alkermes Ligand Pharmaceuticals BioCryst Pharmaceuticals Amicus Therapeutics Celldex Therapeutics Dynavax Technologies MannKind Novavax OPKO Health Geron Alkermes (NASDAQ:ALKS) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership. Does the media favor ALKS or INVA? In the previous week, Alkermes had 10 more articles in the media than Innoviva. MarketBeat recorded 11 mentions for Alkermes and 1 mentions for Innoviva. Alkermes' average media sentiment score of 1.10 beat Innoviva's score of 0.00 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ALKS or INVA more profitable? Alkermes has a net margin of 23.30% compared to Innoviva's net margin of -16.15%. Alkermes' return on equity of 27.52% beat Innoviva's return on equity.Company Net Margins Return on Equity Return on Assets Alkermes23.30% 27.52% 17.98% Innoviva -16.15%15.77%8.41% Do insiders and institutionals hold more shares of ALKS or INVA? 95.2% of Alkermes shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 4.4% of Alkermes shares are held by insiders. Comparatively, 2.3% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable valuation & earnings, ALKS or INVA? Alkermes has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.56B3.04$367.07M$2.0913.76Innoviva$358.71M3.36$23.39M-$1.01-19.01 Which has more volatility & risk, ALKS or INVA? Alkermes has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Do analysts prefer ALKS or INVA? Alkermes currently has a consensus price target of $40.00, indicating a potential upside of 39.13%. Innoviva has a consensus price target of $55.00, indicating a potential upside of 186.46%. Given Innoviva's stronger consensus rating and higher possible upside, analysts plainly believe Innoviva is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83Innoviva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAlkermes beats Innoviva on 13 of the 17 factors compared between the two stocks. Get Innoviva News Delivered to You Automatically Sign up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INVA vs. The Competition Export to ExcelMetricInnovivaLarge Cap Pharma IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.21B$251.92B$5.53B$9.04BDividend YieldN/A2.86%5.24%4.02%P/E Ratio-19.0127.6227.5820.25Price / Sales3.364.99417.23118.60Price / Cash5.6113.8136.8958.07Price / Book1.7417.618.035.67Net Income$23.39M$8.49B$3.18B$249.21M7 Day Performance-3.81%1.04%2.91%3.28%1 Month Performance-9.31%0.73%3.72%5.56%1 Year Performance17.36%-3.27%36.04%21.13% Innoviva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INVAInnoviva3.912 of 5 stars$19.20-1.0%$55.00+186.5%+17.6%$1.21B$358.71M-19.01100Positive NewsALKSAlkermes4.9369 of 5 stars$29.26+0.6%$40.00+36.7%+18.7%$4.80B$1.56B14.001,800Positive NewsAnalyst RevisionLGNDLigand Pharmaceuticals4.7765 of 5 stars$114.97+0.8%$146.14+27.1%+38.3%$2.20B$167.13M-16.1580News CoveragePositive NewsBCRXBioCryst Pharmaceuticals4.473 of 5 stars$9.91-1.9%$16.56+67.1%+39.5%$2.11B$450.71M-38.12530Analyst ForecastAnalyst RevisionFOLDAmicus Therapeutics3.7053 of 5 stars$5.71+1.2%$16.22+184.1%-37.3%$1.74B$528.29M-63.44480CLDXCelldex Therapeutics3.1004 of 5 stars$20.39-0.5%$50.11+145.8%-38.8%$1.36B$7.02M-7.55150DVAXDynavax Technologies4.1987 of 5 stars$9.77-2.2%$24.00+145.6%-6.7%$1.20B$277.25M-18.79350MNKDMannKind2.6305 of 5 stars$3.80+0.8%$10.33+171.9%-28.3%$1.15B$285.50M38.00400NVAXNovavax4.4897 of 5 stars$6.31-1.6%$17.00+169.4%-45.9%$1.04B$682.16M2.381,990OPKOPKO Health4.4624 of 5 stars$1.27-1.6%$2.75+116.5%+10.7%$1.02B$713.10M-18.142,997GERNGeron2.7184 of 5 stars$1.42-6.0%$5.06+256.5%-67.3%$961.75M$76.99M-6.7670 Related Companies and Tools Related Companies Alkermes Alternatives Ligand Pharmaceuticals Alternatives BioCryst Pharmaceuticals Alternatives Amicus Therapeutics Alternatives Celldex Therapeutics Alternatives Dynavax Technologies Alternatives MannKind Alternatives Novavax Alternatives OPKO Health Alternatives Geron Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INVA) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innoviva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INVA Stock Alerts